Agoracom: Small Cap Investment - Resverlogix Corp. - Re: IP considerations may prevent RVX from disclosing eGFR data

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

IP considerations may prevent RVX from disclosing eGFR data

BKC

Jun 08, 2020 03:35PM

Re: IP considerations may prevent RVX from disclosing eGFR data

cityslicker99

Jun 08, 2020 05:43PM

Re: IP considerations may prevent RVX from disclosing eGFR data

KOO-KOO2

Jun 08, 2020 06:02PM

cityslicker99

Rank: President [?]

Points: 1942 [?]

Votes: 24 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: IP considerations may prevent RVX from disclosing eGFR data

in response to

Re: IP considerations may prevent RVX from disclosing eGFR data

KOO-KOO2

posted on Jun 08, 2020 06:25PM

I see. Thanks. Even so, if the reason for not including an effect on GFR was to allow a patent filing, it would presumably mean they still can't present the data at the meeting, because (to our knowledge at least) no such patent has been filed. If they had wanted to file for the statin + apabetalone effect on GFR, surely they would have done so by now. No?

3 Recommendations

Re: IP considerations may prevent RVX from disclosing eGFR data

KOO-KOO2

Jun 08, 2020 06:38PM

Re: IP considerations may prevent RVX from disclosing eGFR data

Mazola

Jun 08, 2020 08:52PM

Re: IP considerations may prevent RVX from disclosing eGFR data

cityslicker99

Jun 09, 2020 01:06PM

Reply New Message

Back To Forum List View

Please to post a reply